2026 CME Session 1: To Biosimilar or Not to Biosimilar

LEARNING OBJECTIVES

After participating in this activity, learners will be able to:

1. Evaluate clinical evidence supporting the use of biosimilar and branded anti-VEGF therapies in wet AMD, DME, and DR.
2. Differentiate patient scenarios in which biosimilars may be appropriate versus when branded anti-VEGF therapies are warranted.
3. Apply patient-centered and health-economic considerations when selecting and adjusting anti-VEGF treatment strategies.
4. Implement appropriate monitoring and switching strategies based on clinical response and individual patient factors.